{
    "clinical_study": {
        "@rank": "137892", 
        "arm_group": [
            {
                "arm_group_label": "Caspofungin", 
                "arm_group_type": "Experimental", 
                "description": "Caspofungin 2 mg/kg intravenous once daily for \u226514 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment"
            }, 
            {
                "arm_group_label": "Amphotericin B Deoxycholate", 
                "arm_group_type": "Active Comparator", 
                "description": "Amphotericin B deoxycholate 1 mg/kg intravenous once daily for \u226514 days after documented negative culture and improvement of clinical signs and symptoms, for a maximum of 90 days treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the safety, tolerability, and efficacy of caspofungin as compared\n      with amphotericin B deoxycholate in the treatment of invasive candidiasis in neonates and\n      infants. The primary hypothesis to be tested in the study is that caspofungin will be\n      superior to amphotericin B deoxycholate with regard to the proportion of participants with\n      fungal-free survival at the 2-week posttherapy follow-up visit."
        }, 
        "brief_title": "Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Candidiasis, Invasive", 
        "condition_browse": {
            "mesh_term": [
                "Candidiasis", 
                "Candidiasis, Invasive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Culture-confirmed invasive Candida infection\n\n        Exclusion Criteria:\n\n          -  Candida disease limited to the oropharynx, esophagus, or other mucosal or superficial\n             skin surfaces\n\n          -  Positive culture for Candida only from sputum, broncho-alveolar lavage, catheter tip,\n             or previously placed indwelling non-vascular catheters or drains\n\n          -  Prosthetic device as the suspected site of Candida infection\n\n          -  Active co-infection with a non-Candida fungal organism\n\n          -  Received >48 hours of systemic antifungal treatment since the positive Candida index\n             culture was collected as therapy for the present episode of invasive candidiasis\n\n          -  Failed prior systemic antifungal therapy for the present episode of invasive\n             candidiasis\n\n          -  Diagnosis of acute hepatitis or cirrhosis\n\n          -  Scheduled or anticipated to receive rifampin or other systemic antifungal therapy\n             while on study therapy\n\n          -  History (including participant's mother) of allergy, hypersensitivity, or any serious\n             reaction to caspofungin or other member of the echinocandin class, or to amphotericin\n             B deoxycholate or other member of the polyene class\n\n          -  Severe congenital disorder known to lower immune response"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "3 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01945281", 
            "org_study_id": "0991-064"
        }, 
        "intervention": [
            {
                "arm_group_label": "Caspofungin", 
                "intervention_name": "Caspofungin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Amphotericin B Deoxycholate", 
                "intervention_name": "Amphotericin B Deoxycholate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amphotericin B", 
                "Liposomal amphotericin B", 
                "Amphotericin B, deoxycholate drug combination", 
                "Caspofungin", 
                "Echinocandins", 
                "Deoxycholic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 27, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Call for Information (Investigational Site 0061)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Francesca Carvajal", 
                    "phone": "57 1219109011090"
                }, 
                "facility": {
                    "address": {
                        "city": "Bogota", 
                        "country": "Colombia"
                    }, 
                    "name": "MDS Colombia SAS"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alev Eren", 
                    "phone": "90 212 336 12 63"
                }, 
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey"
                    }, 
                    "name": "Merck Sharp & Dohme Ilaclari Ltd. Sti"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Colombia", 
                "Turkey"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants Less Than 3 Months of Age", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of Participants with Fungal-free Survival Through the 2-week Posttherapy Period", 
            "safety_issue": "No", 
            "time_frame": "Up to 104 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01945281"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of Participants with Fungal-free Survival Through the End of Study Treatment", 
            "safety_issue": "No", 
            "time_frame": "Up to 90 days"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}